- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00031434
Valganciclovir in Congenital CMV Infants
A Phase I/II Pharmacokinetic and Pharmacodynamic Evaluation of Oral Valganciclovir in Neonates With Symptomatic Congenital Cytomegalovirus (CMV) Infection (CASG 109)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202-3591
- University of Arkansas
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
Stanford, California, United States, 94305
- Stanford University
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- University of Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Stroger Cook Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202-3830
- University of Louisville
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St. Louis
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-2162
- Creighton University
-
-
New York
-
Manhasset, New York, United States, 11030
- Schneider Children's Hospital
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Ohio
-
Cleveland, Ohio, United States, 44109-1998
- MetroHealth Medical Center
-
Columbus, Ohio, United States, 43205
- Ohio State University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, United States, 75390-9063
- The University of Texas Southwestern Medical Center
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
Galveston, Texas, United States, 77555
- The University of Texas Medical Branch
-
San Antonio, Texas, United States, 78229
- The University of Texas Health Science Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent from parent(s) or legal guardian(s).
- Culture confirmation of cytomegalovirus (CMV) from urine or throat swab specimens.
- Symptomatic congenital CMV disease, as manifest by one or more of the following:
Thrombocytopenia Petechiae Hepatomegaly Splenomegaly Intrauterine growth restriction Hepatitis (elevated transaminases and/or bilirubin) Central nervous system involvement of the CMV disease (such as microcephaly, radiographic abnormalities indicative of CMV CNS disease, abnormal CSF indices for age, chorioretinitis, hearing deficits as detected by brainstem evoked response, and/or positive CMV PCR from CSF)
- Less than or equal to 30 days of age at study enrollment.
- Weight at study enrollment greater than or equal to 1800 grams.
- Gestational age greater than or equal to 32 weeks.
Exclusion Criteria:
- Imminent demise.
- Patients receiving other antiviral agents or immune globulin.
- Gastrointestinal abnormality which might preclude absorption of an oral medication (e.g., a history of necrotizing enterocolitis).
- Creatinine clearance < 10mL/min/1.73 square meters at time of study enrollment.
- Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
|
Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption.
Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles.
The beginning oral valganciclovir dose under investigation is 14 mg/kg.
The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function.
Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution.
The dose of intravenous ganciclovir is 6 mg/kg.
Intravenous ganciclovir will be adjusted for the baby's weight and renal function.
Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of ganciclovir following administration of oral valganciclovir syrup. The pharmacokinetics will be assessed by a population approach to PK data analysis.
Time Frame: Day 1: 0.25-0.75, 1-3, 5-7, and 10-12 hours. Day 3: with 2nd dose of IV ganciclovir, before dose, 1 hour, 2-3, 5-7, and 10-12 hours after dose. 1 and 2 weeks post oral valganciclovir: 0.5 after the am dose and 3 hours after the 1st PK.
|
Day 1: 0.25-0.75, 1-3, 5-7, and 10-12 hours. Day 3: with 2nd dose of IV ganciclovir, before dose, 1 hour, 2-3, 5-7, and 10-12 hours after dose. 1 and 2 weeks post oral valganciclovir: 0.5 after the am dose and 3 hours after the 1st PK.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of valganciclovir following administration of oral valganciclovir syrup.
Time Frame: Day 1: 0.25-0.75, 1-3, 5-7, and 10-12 hours. 1 and 2 weeks post oral valganciclovir: 0.5 after the am dose and 3 hours after the 1st PK.
|
Day 1: 0.25-0.75, 1-3, 5-7, and 10-12 hours. 1 and 2 weeks post oral valganciclovir: 0.5 after the am dose and 3 hours after the 1st PK.
|
Lack of vomiting and/or diarrhea associated with administration of oral valganciclovir syrup.
Time Frame: Assessed through Day 56.
|
Assessed through Day 56.
|
Correlation of ganciclovir plasma concentrations following administration of intravenous ganciclovir and oral valganciclovir syrup with CMV whole blood viral load.
Time Frame: Day 1 (prior to dose 1 of valganciclovir), Day 7, Day 14, Day 28, Day 42, Day 56, and 6 months.
|
Day 1 (prior to dose 1 of valganciclovir), Day 7, Day 14, Day 28, Day 42, Day 56, and 6 months.
|
Assessment of toxicity, such as neutropenia, associated with the administration of oral valganciclovir syrup.
Time Frame: Duration of study.
|
Duration of study.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-595
- CASG 109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Infections
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
Mayo ClinicCompletedCytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Institut PasteurCompletedCongenital Cytomegalovirus InfectionFrance
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionsUnited States, Australia, Canada, Finland, Israel, Russian Federation, Spain
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
Clinical Trials on Valganciclovir
-
Luis Eduardo Morales BuenrostroCompletedKidney Transplantation | Pharmacokinetics | Cytomegalovirus Infections | Therapeutic EquivalencyMexico
-
Stanford UniversityCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Weill Medical College of Cornell University; University of North Carolina, Chapel Hill and other collaboratorsCompletedSarcomaUnited States
-
Rabin Medical CenterCompletedInfection in Solid Organ Transplant RecipientsIsrael
-
University of California, San FranciscoRoche Pharma AGCompletedHIV Infections | Cytomegalovirus InfectionsUnited States
-
Hoffmann-La RocheCompletedCytomegalovirus InfectionsUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Scott PalmerRoche Pharma AGCompletedCytomegalovirus InfectionsUnited States
-
Karolinska InstitutetKarolinska University HospitalCompletedGlioblastoma Multiforme | Cytomegalovirus InfectionSweden